1640292-55-2 Usage
Description
Oclacitinib maleate is a novel Janus kinase (JAK) inhibitor, a class of enzymes that play a crucial role in cytokine signaling pathways. It is specifically designed to target and inhibit the activity of JAK enzymes, which are involved in the regulation of immune responses and inflammation. By inhibiting these enzymes, oclacitinib maleate can help reduce inflammation and alleviate symptoms associated with various allergic conditions.
Uses
Used in Pharmaceutical Industry:
Oclacitinib maleate is used as an anti-inflammatory and immunosuppressive agent for the treatment of various allergic conditions, such as atopic dermatitis, asthma, and allergic rhinitis. Its ability to inhibit JAK enzymes helps in reducing inflammation and immune responses, providing relief from allergy symptoms.
Used in Veterinary Medicine:
In addition to human applications, oclacitinib maleate is also used in veterinary medicine as an anti-inflammatory and immunosuppressive agent for the treatment of allergic conditions in pets, such as canine atopic dermatitis. It helps in managing the symptoms and improving the quality of life for pets suffering from allergies.
Used in Research:
Oclacitinib maleate is also used as a research tool in the study of JAK enzymes and their role in immune responses and inflammation. It can be employed in various experimental setups to investigate the effects of JAK inhibition on cytokine signaling pathways and the development of potential therapeutic agents targeting these pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 1640292-55-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,4,0,2,9 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1640292-55:
(9*1)+(8*6)+(7*4)+(6*0)+(5*2)+(4*9)+(3*2)+(2*5)+(1*5)=152
152 % 10 = 2
So 1640292-55-2 is a valid CAS Registry Number.
1640292-55-2Relevant articles and documents
Preparation method of 7H-pyrrolo [2, 3-d] pyrimidine compound
-
, (2021/01/30)
The invention discloses a preparation method of a 7H-pyrrolo [2, 3-d] pyrimidine compound. The full name of the 7H-pyrrolo [2, 3-d] pyrimidine compound is trans-N-methyl-4-(methyl-7H-pyrrolo [2, 3-d]pyrimidine-4-yl amino) cyclohexylmethanesulfonamide male
SOLID STATE FORMS OF OCLACITINIB MALEATE
-
Page/Page column 13-14, (2020/08/22)
The present invention relates to solid state forms of oclacitinib maleate and methods for the preparation of the solid state forms of oclacitinib maleate. The solid state forms of oclacitinib maleate of the present invention include amorphous oclacitinib maleate, crystalline tetramethyl urea solvate form of oclacitinib maleate, crystalline monohydrate form of oclacitinib maleate and crystalline form of oclacitinib maleate (form B).
PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS
-
, (2017/09/02)
Described herein are improved processes for the preparation of the 7H-pyrrolo[2,3-d]pyrimidine compound, N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}-methanesulfonamide, intermediates thereof, and veterinary acceptable salts thereof.
